Drug Trial Radar · NCT03092856
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Actual
Start
Jul 19, 2017
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
Conditions
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Cancer
- Recurrent Renal Cell Carcinoma
- Stage IV Renal Cell Cancer
Interventions
Anti-OX40 Antibody PF-04518600Biological
Given IV
AxitinibDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
PlaceboOther
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Time from randomization until the earliest of documented disease progression (confirmed progression of disease) or death, assessed for up to 180 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
University of Kansas Cancer Center
Kansas City, Kansas
Weill Cornell Medical College, New York- Presbyterian Hospital
New York, New York
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania
University of Virginia Cancer Center
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.